Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform across North East London, adding 70 community pharmacy sites, building on successful NHS-linked cardiovascular programs with Barts Health NHS Trust [1][2] Company Strategy - The deployment reflects strong pharmacy engagement and increasing clinical demand, aligning with NHS priorities to shift care from hospitals to community settings [2][4] - Avricore's strategic focus on the UK demonstrates the scalability of HealthTab™ within complex NHS environments, positioning it for further growth in preventive and treatment-linked care pathways across England [4] HealthTab™ Platform - HealthTab™ is a comprehensive solution for community-based point-of-care testing (POCT) networks, integrating instruments, cloud software, standardized workflows, and training [5] - The platform ensures quality-assured testing and real-time analytics for public health reporting, reducing implementation complexity for participating sites [6] Quality Assurance - HealthTab™ meets high standards of analytical performance through a partnership with CEQAL Inc., ensuring a comprehensive quality management program [7] - The program includes centralized monitoring of reagents, internal quality-control procedures, and regular external quality-assessment events to support accuracy and consistency [8] Company Overview - Avricore Health Inc. focuses on acquiring and developing early-stage technologies to advance pharmacy practice and patient care, aiming to create the largest network of rapid testing devices in community pharmacies [9]

Company Overview - Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care [5] - The company's flagship offering, HealthTab™, aims to create the world's largest network of rapid testing devices in community pharmacies [5] Stock Options Announcement - The board of directors of Avricore has approved the granting of stock options for a total of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1] - The options will vest quarterly starting from the date of grant and will expire 5 years from the grant date, contingent on the optionees remaining in their roles [2] HealthTab™ Product Details - HealthTab™ is a point-of-care testing solution that provides lab-accurate results from just a few drops of blood, with real-time data reporting [3] - The test menu includes up to 23 key biomarkers for chronic disease management, including diabetes and heart disease, and has recently added capabilities for bacterial and viral tests [3] HealthTab™ Network Model - The HealthTab™ network model enhances the role of pharmacists in primary care delivery and empowers patients to take control of their health [4] - It aims to reduce costs and waiting times while providing multiple revenue streams, including equipment leasing, direct access testing, and decentralized clinical trials [4]

Core Insights - Avricore Health Inc. is expanding its HealthTab™ platform in the UK, emphasizing the role of pharmacists in chronic disease prevention and management [1][2] - The UK government is significantly investing in community pharmacies, with £645 million (approx. CAD $1.2 billion) pledged in 2024 and £617 million (approx. CAD $1.144 billion) in 2025 to enhance pharmacy-led services [5] - The company has concluded operations in Shoppers Drug Mart locations in Canada as of March 31, 2025, allowing for the redeployment of devices in Canada and the UK [3][4] Financial Performance - In 2024, total revenue increased by 37% year over year to $4,785,711, while gross profit rose by 56% to $1,880,306 [11] - The company reported a loss from operations of $668,977 in 2024, an improvement from a loss of $701,215 in 2023 [8] - Total assets decreased to $2,298,544 in 2024 from $2,538,205 in 2023, while total current liabilities dropped to $330,817 from $529,218 [8] HealthTab™ Expansion - The HealthTab™ platform launched in North East London in November 2024, targeting areas with high cardiovascular disease burdens [13] - The initiative is supported by local health authorities and aims to integrate with NHS digital systems to modernize care pathways [13][14] - The platform has already conducted over 930,000 blood pressure screenings in 6,000 pharmacies, demonstrating strong uptake [14][6] Future Strategy - The company plans to expand HealthTab™ into other major population centers in the UK, focusing on diverse demographics suitable for preventative health programs [15] - Following initial successes, the company aims to work with NHS stakeholders for broader adoption of HealthTab™, potentially integrating cholesterol testing into the Pharmacy First protocol [16] - Momentum is expected to grow throughout 2025 as NHS plans for expanding point-of-care testing in community pharmacies become clearer [17] Market Context - The point-of-care testing market is projected to reach $93.21 billion USD by 2030, indicating significant growth potential for HealthTab™ [19] - The UK government’s investment in pharmacy-led services aligns with the increasing demand for accessible healthcare solutions amid rising chronic disease rates [5][6]